These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 14677085)

  • 1. Individualized medicine - implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders.
    Kirchheiner J; Bertilsson L; Bruus H; Wolff A; Roots I; Bauer M
    Pharmacopsychiatry; 2003 Nov; 36 Suppl 3():S235-43. PubMed ID: 14677085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics-guided dose modifications of antidepressants.
    Seeringer A; Kirchheiner J
    Clin Lab Med; 2008 Dec; 28(4):619-26. PubMed ID: 19059066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current topics in pharmacokinetics and pharmacogenetics of antidepressant drugs].
    Gex-Fabry M; Bertschy G; Kosel M; Ferrero F
    Rev Med Suisse; 2009 Sep; 5(217):1808, 1810-3. PubMed ID: 19839368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of pharmacogenetics in the treatment of depression and anxiety disorders.
    Schosser A; Kasper S
    Int Clin Psychopharmacol; 2009 Nov; 24(6):277-88. PubMed ID: 19738481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [5-HT1A gene polymorphisms contributed to antidepressant response in major depression].
    Kato M; Fukuda T; Wakeno M; Okugawa G; Takekita Y; Serretti A; Azuma J; Kinoshita T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2009 Feb; 29(1):23-31. PubMed ID: 19326813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haplotype analysis of single nucleotide polymorphisms in the vascular endothelial growth factor (VEGFA) gene and antidepressant treatment response in major depressive disorder.
    Tsai SJ; Hong CJ; Liou YJ; Chen TJ; Chen ML; Hou SJ; Yen FC; Yu YW
    Psychiatry Res; 2009 Sep; 169(2):113-7. PubMed ID: 19700204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomics of antidepressant drugs.
    Horstmann S; Binder EB
    Pharmacol Ther; 2009 Oct; 124(1):57-73. PubMed ID: 19563827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacogenetics and tailored drug treatment in schizophrenia].
    Andreassen OA; Steen VM
    Tidsskr Nor Laegeforen; 2006 Sep; 126(18):2400-2. PubMed ID: 16998555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Possibility of a pharmacogenetic approach for prediction and personalized medication in major depressive disorder treatment].
    Kato M
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Apr; 30(2):83-92. PubMed ID: 20491282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does pretreatment testing for serotonin transporter polymorphisms lead to earlier effects of drug treatment in patients with major depression? A decision-analytic model.
    Smits KM; Smits LJ; Schouten JS; Peeters FP; Prins MH
    Clin Ther; 2007 Apr; 29(4):691-702. PubMed ID: 17617292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics and the concept of individualized medicine.
    Shastry BS
    Pharmacogenomics J; 2006; 6(1):16-21. PubMed ID: 16302022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Importance of genetic polymorphism of cytochrome P450 isoenzymes for the choice and regimes of antidepressant and antipsychotic dosing on an individual basis].
    Savel'eva MI; Sychev DA; Kazakov RE; Ignat'ev IV; Tishenova A; Gasanov NA; Ramenskaia GV; Kukes VG
    Klin Med (Mosk); 2008; 86(11):22-8. PubMed ID: 19177788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes.
    Kirchheiner J; Seeringer A
    Biochim Biophys Acta; 2007 Mar; 1770(3):489-94. PubMed ID: 17113714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerance to desvenlafaxine in rapid metabolizing depressed patients.
    Parker GB; Brotchie HL; Hyett M
    Int Clin Psychopharmacol; 2011 Mar; 26(2):84-7. PubMed ID: 21119521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Individualized pharmacotherapy based on cytochrome P-450 (CYP) genotyping].
    Johansen PW; Bergan S; Rootwelt H; Kvittingen EA; Rugstad HE
    Tidsskr Nor Laegeforen; 2002 Nov; 122(29):2781-3. PubMed ID: 12523145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonin receptor 1A-1019C/G variant: impact on antidepressant pharmacoresponse in melancholic depression?
    Baune BT; Hohoff C; Roehrs T; Deckert J; Arolt V; Domschke K
    Neurosci Lett; 2008 May; 436(2):111-5. PubMed ID: 18387740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment.
    Tzvetkov MV; Brockmöller J; Roots I; Kirchheiner J
    Pharmacogenet Genomics; 2008 Jun; 18(6):495-506. PubMed ID: 18496129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacogenetics of antidepressant metabolism. Value of the debrisoquin test].
    Baumann P
    Encephale; 1986; 12(4):143-8. PubMed ID: 3792273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Support for the involvement of the KCNK2 gene in major depressive disorder and response to antidepressant treatment.
    Liou YJ; Chen TJ; Tsai SJ; Yu YW; Cheng CY; Hong CJ
    Pharmacogenet Genomics; 2009 Oct; 19(10):735-41. PubMed ID: 19741570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of Serotonin Transporter Promoter Polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments.
    Serretti A; Benedetti F; Zanardi R; Smeraldi E
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jul; 29(6):1074-84. PubMed ID: 15939518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.